Bristol-Myers Squibb & Celgene Combined Could Generate Earnings of $6 Per Share In The Coming Years

Bristol-Myers Squibb (NYSE:BMY) announced that it has agreed to acquire Celgene Inc. for $50 per share in cash and one share of Bristol-Myers Squibb for each share of Celgene, which translates into a $74 billion transaction value and $90 billion if we include the debt. Additionally, Celgene share...